Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Revenue of Arcellx, Inc. (ACLX)
Revenue in 2023 (TTM): $110.32 M
According to Arcellx, Inc.'s latest financial reports the company's current revenue (TTM) is $110.32 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Arcellx, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $110.32 M | $110.32 M | $-64,145,000 | $-70,027,000 | $-70,690,000 |
| 2022 | $ | $-2,224,000 | $-184,735,000 | $-188,679,000 | $-186,099,000 |
| 2021 | $ | $-1,040,999 | $-63,928,000 | $-64,969,000 | $-63,928,000 |
| 2020 | $ | $-629,000 | $-31,467,000 | $-32,095,000 | $-32,095,000 |
| 2019 | $ | $-326,000 | $-17,646,000 | $-17,972,000 | $-17,972,000 |
| 2018 | $ | $ | $-8,215,999 | $-8,308,000 | $-8,308,000 |